Treace Medical price target lowered to $9.50 from $10 at Truist

Truist lowered the firm’s price target on Treace Medical (TMCI) to $9.50 from $10 and keeps a Hold rating on the shares after its recent non-deal roadshow with CEO John Treace. Discussions mostly centered on Lapiplasty competition and new MIS Osteotomy launches, which – along with higher Lapiplasty reimbursement – should allow revenue growth to re-accelerate back to 10% ore more in Q2-Q4, the analyst tells investors in a research note. The firm remains on hold however pending greater confidence that new rollouts can sustain double-digit growth beyond easy 2025 comps, Truist adds.